

Human OX40 (CD134) Protein (C-His)

| | |
|---------------------------|--------------------------------------|
| Catalog Number: | 817901, 817902 |
| Size: | 25 ug, 100 ug |
| Target Name: | TNFRSF4, OX40, CD134, OX40L receptor |
| Regulatory Status: | RUO |


PRODUCT DETAILS

| | |
|-------------------------------|--|
| Application: | ELISA, BLI |
| Format: | Liquid, Purified |
| Expression Host: | CHO |
| Species: | Human |
| Sources: | Recombinant Human OX40 (Lue29-Ala216) with C-terminus His-tag is expressed in CHO cell. |
| Accession Number: | P43489 |
| Molecular Weight: | The protein has a predicted molecular weight of 21.7 kDa. Under DTT-reducing conditions, it migrates at approximately 40 kDa on SDS-PAGE. |
| Affinity Tag: | C-His |
| Purity: | >95% based on SDS-PAGE under reducing condition |
| Formulation: | 1xPBS buffer, pH7.4, 0.22 µm filtered |
| Endotoxin level: | Not tested |
| Protein Concentration: | 25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a lot-specific concentration. |
| Storage and Handling: | Briefly centrifuge the vial upon receipt. An unopened vial can be stored at 4°C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22 µm-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at ≤ -70°C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability. |

BACKGROUND INFORMATION

OX40 (CD134) and its ligand OX40L (CD252), both part of the TNF receptor superfamily, play a key role in immune regulation. Their interaction is essential for T-cell expansion, survival, and cytokine production, influencing T cells, antigen-presenting cells, NK cells, and NKT cells. OX40-OX40L signaling helps break immune tolerance in malignancies, promoting antitumor immunity, and is also involved in the development of inflammatory and autoimmune diseases. Due to these regulatory effects, the OX40-OX40L pathway is a promising target for therapeutic interventions in both cancer and infectious diseases, with OX40 stimulation showing potential for therapeutic immunization strategies.

PRODUCT DATA



Human OX40 protein (C-His) on SDS-PAGE under reducing condition (P+) and non-reducing condition (P-). The gel was stained for 1 hour with BlinkBlue (catalog 700102). The purity of this protein appears to be greater than 95% based on reducing conditions.